# Dulaglutide

Canonical source: https://retacompare.com/encyclopedia/dulaglutide

Once-weekly GLP-1 receptor agonist. Half-life extension via FcRn recycling.

Reference facts

Also known asTrulicityCategoryGLP-1 & MetabolicMechanism of actionOnce-weekly GLP-1 receptor agonist. Half-life extension via FcRn recycling.TargetsGLP-1RIndications under research or approvedType 2 Diabetes, Cardiovascular Risk ReductionRegulatory status (reference entry)FDA-approved (2014)Half-life~120 hours (~5 days)SequenceHGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGSequence notesTwo GLP-1(7-37) analog peptides with Gly8/Glu22/Gly36 substitutions, linked via flexible peptide spacers to a human IgG4 Fc fragment.Molecular weight (Da)59670Originator / sponsorEli LillyFirst reported2010OriginEngineered as an Fc-fusion to provide weekly dosing without fatty-acid acylation.
    Primary References

REWIND cardiovascular outcomes, Lancet 2019

FDA Trulicity label


    Explore research articles about Dulaglutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- REWIND cardiovascular outcomes, Lancet 2019: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext
- FDA Trulicity label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf